Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455595 | 0.86 | CYP4F2 (0.52) | CYP4F2CYP4A11CA2TSHRSMN1; SMN2 | |
| SCHEMBL8114167 | 0.86 | CYP4F2 (0.52) | CYP4F2CYP4A11CA2TSHRSMN1; SMN2 | |
| SCHEMBL8115498 | 0.86 | TSHR (0.55) | CYP4F2CYP4A11CA2TSHRSMN1; SMN2 | |
| SCHEMBL24330535 | 0.85 | TDP1 (0.53) | TSHRSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL29015042 | 0.84 | MAPT (0.53) | CYP4F2CYP4A11CA2TSHRSMN1; SMN2 | |
| SCHEMBL132039 | 0.84 | CA2 (0.64) | CYP4F2CYP4A11CA2TSHRCA12 | |
| SCHEMBL7455946 | 0.83 | LMNA (0.53) | TSHRLMNANPC1RAB9AMAPT | |
| SCHEMBL7457332 | 0.83 | LMNA (0.53) | TSHRLMNANPC1RAB9AMAPT | |
| Lithium Ion SCHEMBL28897638 | 0.83 | CA2 (0.53) | CYP4F2CYP4A11CA2TSHRSMN1; SMN2 | |
| SCHEMBL28448724 | 0.83 | CA2 (0.53) | CYP4F2CYP4A11CA2TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349056-B | Antiviral agent for hepatitis B virus infection | 南京安纳康生物科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-111393391-B | Antiviral agent for hepatitis B virus infection | 南京安纳康生物科技有限公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-111393391-A | Antiviral agent for hepatitis B virus infection | 南京安纳康生物科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-111349056-A | Antiviral agent for hepatitis B virus infection | 南京安纳康生物科技有限公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| CN-102282131-B | As the new benzsulfamide of calcium ion channel blockor | ABBVIE INC. (BS) | 2015-08-26 | — | — | CN | disclosed |
| EP-2382191-B1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE BAHAMAS LTD (BS) | 2014-11-12 | — | — | EP | disclosed |
| US-8741899-B2 | (4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[(8aR)-hexahydropyrrolo-[1,2-a]pyrazin-2(1H)-ylcarbonyl]-benzenesulfonamide, and pharmaceutically acceptable salts thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8404719-B2 | Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-8101614-B2 | Substituted pyrrolo [1,2-a] pyrazines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| CN-102282131-A | Novel benzenesulfonamides as calcium channel blockers | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2382191-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010083264-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
| EP-1020434-A1 | 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5250498-A | Applying to weeds | BAYER AKTIENGESELLSCHAFT (DE) | 1993-10-05 | — | — | US | disclosed |
| EP-0432600-A2 | Derivatives of 2-iminopyridine | BAYER AG (DE) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | CYP4F2 1955/4885CYP4A11 3520/4885CA2 3378/4885 |
| US-20120083499-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | CYP4F2 1374/4885CYP4A11 1068/4885CA2 137/4885 |
| US-20100197693-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, RYR2, RYR1 | CYP4F2 1374/4885CYP4A11 1068/4885CA2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.